Trial reportMemorias do Instituto Oswaldo Cruz2015
A randomised double-blind clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D-213/77 in children nine-23 months old.
Trial report in Memorias do Instituto Oswaldo Cruz, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Duration of Protection After Vaccination Against Yellow Fever: A Systematic Review and Meta-Analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Pooled it
- A Meta-Analysis of Serological Response Associated with Yellow Fever Vaccination.The American journal of tropical medicine and hygiene · 2016Pooled it
- Immunogenicity of a single dose of the 17DD yellow fever vaccine in a cohort of adults and children in a non-endemic area, and its association with dengue and Zika seropositivity.PLoS neglected tropical diseases · 2025Trial
- Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children.Frontiers in immunology · 2019Trial
- A cohort study of the duration of immunity to yellow fever after 4 years of primary vaccination in children and adults.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2026Article
- Development of a hydrogen peroxide-inactivated vaccine that protects against viscerotropic yellow fever in a non-human primate model.Cell reports. Medicine · 2024Article
- Review
- Yellow fever virus vaccination: an emblematic model to elucidate robust human immune responses.Human vaccines & immunotherapeutics · 2021Article
- Article
- Serological Protection 5-6 Years Post Vaccination Against Yellow Fever in African Infants Vaccinated in Routine Programmes.Frontiers in immunology · 2020Article
- Yellow fever control: current epidemiology and vaccination strategies.Tropical diseases, travel medicine and vaccines · 2020Review
- Long-term immunity against yellow fever in children vaccinated during infancy: a longitudinal cohort study.The Lancet. Infectious diseases · 2019Article
- Role of Multivalency and Antigenic Threshold in Generating Protective Antibody Responses.Frontiers in immunology · 2019Review
- Seroepidemiology of Dengue, Zika, and Yellow Fever Viruses among Children in the Democratic Republic of the Congo.The American journal of tropical medicine and hygiene · 2018Article
- Yellow fever vaccine and risk of developing serious adverse events: a systematic review.Revista panamericana de salud publica = Pan American journal of public health · 2018Review
- Questions regarding the safety and duration of immunity following live yellow fever vaccination.Expert review of vaccines · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This randomised, double-blind, multicentre study with children nine-23 months old evaluated the immunogenicity of yellow fever (YF) vaccines prepared with substrains 17DD and 17D-213/77. YF antibodies were titered before and 30 or more days after vaccination. Seropositivity and seroconversion were analysed according to the maternal serological status and the collaborating centre. A total of 1,966 children were randomised in the municipalities of the states of Mato Grosso do Sul, Minas Gerais and São Paulo and blood samples were collected from 1,714 mothers. Seropositivity was observed in 78.6% of mothers and 8.9% of children before vaccination. After vaccination, seropositivity rates of 81.9% and 83.2%, seroconversion rates of 84.8% and 85.8% and rates of a four-fold increase over the pre-vaccination titre of 77.6% and 81.8% were observed in the 17D-213/77 and 17DD subgroups, respectively. There was no association with maternal immunity. Among children aged 12 months or older, the seroconversion rates of 69% were associated with concomitant vaccination against measles, mumps and rubella. The data were not conclusive regarding the interference of maternal immunity in the immune response to the YF vaccine, but they suggest interference from other vaccines. The failures in seroconversion after vaccination support the recommendation of a booster dose in children within 10 years of the first dose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.